<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03202459</url>
  </required_header>
  <id_info>
    <org_study_id>56057116.0.0000.5479</org_study_id>
    <nct_id>NCT03202459</nct_id>
  </id_info>
  <brief_title>Prophylaxy of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Surgery</brief_title>
  <official_title>Prophylaxy of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Faculdade de Ciências Médicas da Santa Casa de São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Faculdade de Ciências Médicas da Santa Casa de São Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postoperative nausea and vomiting (PONV) is one of the most commonly reported adverse effects
      of anesthesia. The general incidence of vomiting is approximately 30%, nausea at 50% and the
      PONV rate can go up to 80% in high-risk patients without prophylaxis. Prevention of these
      episodes in high-risk patients improves satisfaction and well-being rates. Therefore, it
      becomes important the adequate control of PONV, aiming at the satisfaction of the patient
      with the procedure, lower costs for the health system as well as reduction of complications
      in the postoperative period. This study aims to evaluate the association of gabapentin or
      pregabalin with dexamethasone in reducing the incidence of PONV in high-risk patients
      undergoing laparoscopic surgeries in the first 48 hours postoperatively as well as to assess
      side effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study included 60 patients at high risk for PONV (Apfel-score 0, I, II, III and IV)
      scheduled for elective laparoscopic surgeries at the Central Surgical Center of Irmandade da
      Santa Casa de Misericórdia in São Paulo. Inclusion criteria will be ASA I or II of either
      sex, in the age range of 18 to 70 years. In this study, the recruited patients will be
      allocated randomly into three groups. The group A will receive oral 600 mg gabapentin 2 h
      before surgery. The group B will receive oral 150 mg pregabalin 2 h before surgery. The Group
      C will receive oral placebo 2 h before surgery and ondansetron 8mg intravenous at the end of
      the surgery. This study is &quot;double-blind&quot;, in which neither the doctor nor the patient knows
      what medicine is being given.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2, 2017</start_date>
  <completion_date type="Anticipated">January 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative Nausea or vomiting M0</measure>
    <time_frame>1 hours</time_frame>
    <description>The occurrence of postoperative nausea or vomiting, in the recovery room, during the first hour after surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative Nausea or vomiting M12</measure>
    <time_frame>12 hours</time_frame>
    <description>The occurrence of postoperative nausea or vomiting, reported by the patient or witnessed by a healthcare provider during the first 12 hours after surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative Nausea or vomiting M24</measure>
    <time_frame>24 hours</time_frame>
    <description>The occurrence of postoperative nausea or vomiting, reported by the patient or witnessed by a healthcare provider during the first 24 hours after surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative Nausea or vomiting M48</measure>
    <time_frame>48 hours</time_frame>
    <description>The occurrence of postoperative nausea or vomiting, reported by the patient or witnessed by a healthcare provider during the first 48 hours after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient demographic data</measure>
    <time_frame>Before surgery</time_frame>
    <description>With a questionnaire will be studied the variables: age, sex, weight, height, BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical Duration</measure>
    <time_frame>First hour after surgery</time_frame>
    <description>Time of surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of postoperative anesthesia stay</measure>
    <time_frame>First hours after surgery</time_frame>
    <description>Time to postoperative anesthesia care unit discharge alive (hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The length of stay in hospital</measure>
    <time_frame>From end of surgery until hospital discharge or 30 days after surgery</time_frame>
    <description>Time of stay in hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to request the first medication for nausea and vomiting</measure>
    <time_frame>First hour after surgery</time_frame>
    <description>Reported by the patient or by a healthcare provider</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of medication</measure>
    <time_frame>During the first 30 days after surgery</time_frame>
    <description>Reported by a healthcare provider</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>During the first 30 days after surgery</time_frame>
    <description>Postoperative complications after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of patient satisfaction</measure>
    <time_frame>Before discharge</time_frame>
    <description>The patient's overall satisfaction will be assessed using point scales (very satisfied, somewhat satisfied, neither satisfied nor dissatisfied, somewhat dissatisfied, very dissatisfied)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Postoperative Complications</condition>
  <condition>Postoperative Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>Active Comparator: Group A - gabapentin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patient will receive oral 600 mg gabapentin 2 h before surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator: Group B - pregabalin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patient will receive oral pregabalin 150 mg 2 h before surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator: Group C - placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The patient will receive oral placebo 2 h before surgery and ondansetron 8mg intravenous at the end of the surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group A - gabapentin 600 mg</intervention_name>
    <description>The patient will receive oral 600 mg gabapentin 2 h before surgery</description>
    <arm_group_label>Active Comparator: Group A - gabapentin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group B - pregabalin</intervention_name>
    <description>The patient will receive oral pregabalin 150 mg 2 h before surgery</description>
    <arm_group_label>Active Comparator: Group B - pregabalin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group C - placebo</intervention_name>
    <description>The patient will receive oral placebo 2 h before surgery and ondansetron 8mg intravenous at the end of the surgery</description>
    <arm_group_label>Placebo Comparator: Group C - placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing laparoscopic procedures

          -  Apfel Score 0, I, II, III and IV

          -  ASA I / II

        Exclusion Criteria:

          -  Patients with surgery converted to open before thirty minutes of surgery

          -  Patients who were exposed previously to gabapentin or pregabalin Patients who have
             allergy to any medicine used in the study

          -  Patient who have to any cognitive impairment

          -  Illiterate patients

          -  Patients who refuse to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ligia Andrade da Silva Telles Mathias, Doctor</last_name>
    <phone>+ 55 11 99386-0059</phone>
    <email>rtimao@uol.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thiago Grigio, Master</last_name>
    <phone>+55 11 99298-1605</phone>
    <email>grigiotr@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Irmandade da Santa Casa de Misericórdia de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <zip>01221-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thiago Ramos Grigio, Master</last_name>
      <phone>+55 11 99298-1605</phone>
      <email>grigiotr@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ligia Andrade da Silva Telles Mathias, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrícia Mara Beltrame, Medical Residency</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rodolfo Brito Maia, Medical Residency</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paulo Henrique Borges Teixeira Lima, Medical Residency</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <results_reference>
    <citation>Gan TJ, Diemunsch P, Habib AS, Kovac A, Kranke P, Meyer TA, Watcha M, Chung F, Angus S, Apfel CC, Bergese SD, Candiotti KA, Chan MT, Davis PJ, Hooper VD, Lagoo-Deenadayalan S, Myles P, Nezat G, Philip BK, Tramèr MR; Society for Ambulatory Anesthesia. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2014 Jan;118(1):85-113. doi: 10.1213/ANE.0000000000000002. Erratum in: Anesth Analg. 2015 Feb;120(2):494. Anesth Analg. 2014 Mar;118(3):689.</citation>
    <PMID>24356162</PMID>
  </results_reference>
  <results_reference>
    <citation>Pandey CK, Priye S, Ambesh SP, Singh S, Singh U, Singh PK. Prophylactic gabapentin for prevention of postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy: a randomized, double-blind, placebo-controlled study. J Postgrad Med. 2006 Apr-Jun;52(2):97-100.</citation>
    <PMID>16679671</PMID>
  </results_reference>
  <results_reference>
    <citation>Grant MC, Lee H, Page AJ, Hobson D, Wick E, Wu CL. The Effect of Preoperative Gabapentin on Postoperative Nausea and Vomiting: A Meta-Analysis. Anesth Analg. 2016 Apr;122(4):976-85. doi: 10.1213/ANE.0000000000001120.</citation>
    <PMID>26991615</PMID>
  </results_reference>
  <results_reference>
    <citation>Chandrakantan A, Glass PS. Multimodal therapies for postoperative nausea and vomiting, and pain. Br J Anaesth. 2011 Dec;107 Suppl 1:i27-40. doi: 10.1093/bja/aer358.</citation>
    <PMID>22156268</PMID>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2017</study_first_submitted>
  <study_first_submitted_qc>June 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2017</study_first_posted>
  <last_update_submitted>June 27, 2017</last_update_submitted>
  <last_update_submitted_qc>June 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Faculdade de Ciências Médicas da Santa Casa de São Paulo</investigator_affiliation>
    <investigator_full_name>Lígia Andrade da Silva Telles mathias</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Anesthesia</keyword>
  <keyword>Complications</keyword>
  <keyword>Nausea</keyword>
  <keyword>Vomiting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Complications</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>gamma-Aminobutyric Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

